| KAI Pharmaceuticals Signs Agreement for Development and Commercialization of ... - MarketWatch (press release) |
|
|
MarketWatch (press release) Most ESRD patients on dialysis are affected by CKD-MBD, which can lead to significant morbidity and mortality, including bone pain and fractures, vascular calcification and cardiovascular events. KAI is a clinical-stage, biopharmaceutical company with ... Ono Pays Kai $13M for Japanese Rights to Phase II Secondary Hyperparthyrodism Drug Genetic Engineering News ONO PHARMACEUTICAL : Ono Enters License Agreement with KAI Phamaceuticals,Inc |